News about "Lupin"

Lupin Expands Specialty Care Business with VISUfarma Buyout

Lupin Limited has announced the completion of its acquisition of VISUfarma B.V. from GHO Capital Partners LLP, marking a significant step in strengthening its specialty care portfolio and expanding its footprint in Europe.

Lupin | 02/04/2026 | By Darshana

Lupin Gets US FDA Tentative Approval for Pitolisant Tablets

US FDA grants tentative approval to Lupin’s Pitolisant Tablets (4.45 mg, 17.8 mg), bioequivalent to Wakix, for approved indications.

Lupin | 25/03/2026 | By News Bureau

Lupin and Zydus Partner to Co-Market Semaglutide Injection in India

Lupin has secured semi-exclusive rights to co-market Zydus’ Semaglutide injection in India under the brands Semanext and Livarise, while Zydus will continue marketing it under the brand names SEMAGLYNTM, MASHEMATM and ALTERMETM.

Lupin | 18/03/2026 | By News Bureau |  117

Lupin Limited Secures US FDA Approval for Generic Brivaracetam Oral Solution

Lupin has received US FDA approval for its generic brivaracetam oral solution, bioequivalent to Briviact, and has launched the product in the US market targeting partial-onset seizures.

Lupin | 25/02/2026 | By News Bureau |  147

Lupin Secures European Commission Approval for Ranluspec, Biosimilar Ranibizumab

European Commission clears Lupin’s biosimilar ranibizumab, Ranluspec, for multiple retinal disorders; Sandoz to commercialise across the EU, expanding access to affordable biologics.

Lupin | 24/02/2026 | By News Bureau

Lupin Posts 37 percent Q3 Profit Growth on Record US Sales

Lupin Limited reported a 37.4 percent year-on-year increase in net profit for the third quarter ended December 31, 2025, reaching INR 1,180.5 crore, compared with INR 858.9 crore in the same quarter last year.

Lupin | 13/02/2026 | By Darshana |  162

Lupin Resolves Mirabegron Patent Dispute with Astellas in USD 90 Million Settlement

Lupin Limited has reached a USD 90 million settlement to resolve a patent dispute with Japan-based Astellas Pharma concerning Lupin’s generic version of mirabegron, a treatment for overactive bladder. The agreement concludes ongoing litigation in the United States and provides commercial clarity around Lupin’s continued participation in the market.

Lupin | 11/02/2026 | By Darshana |  106

Lupin Launches Topiramate Extended-Release Capsules in US Following FDA Approval

Lupin rolls out FDA-approved generic topiramate extended-release capsules in the US for epilepsy and migraine treatment.

Lupin | 05/02/2026 | By News Bureau |  149

Lupin Partners with Galenicum to Commercialise Injectable Semaglutide

Global pharmaceutical major Lupin Limited has entered into a licensing and supply agreement with Galenicum Health, S.L.U. through its subsidiary, Lupin Atlantis Holdings SA (LAHSA), for finished injectable formulations of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist.

Lupin | 21/01/2026 | By Darshana |  241

Lupin Inks Exclusive Licensing Deal with Neopharmed for Plasil in Brazil and Philippines

Global pharmaceutical major Lupin Limited said its subsidiaries in the Philippines, Multicare Pharmaceuticals, and in Brazil, MedQuimica, have entered into an exclusive licensing agreement with Italy-based Neopharmed Gentili S.p.A. to market and promote the gastroenterology brand Plasil (metoclopramide) in their respective markets.

Lupin | 19/12/2025 | By Darshana |  239